Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?

Basit Öğe Kaydı
dc.contributor.authorDikilitas, Mustafa
dc.date.accessioned2024-08-04T20:48:53Z
dc.date.available2024-08-04T20:48:53Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction HCC remains a challenging disease with its unique characteristics and aggressive behavior. Although there are some curative-intent treatments such as liver transplantation and surgical resection, they themselves did not cure the patients with relatively high recurrence rates. Several modalities including local ablation methods like TACE or TARE, systemic treatments such as chemotherapy, tyrosine kinase inhibitors or antiviral therapies are tested in adjuvant or neoadjuvant setting, but none of them offered a survival benefit (except antiviral therapy in HBV-related HCC). Conclusion After a decade of plateau in drug development, ICPIs came into podium with their different mechanism of action consistent with immunogenic nature of the disease and with high expectations, and ongoing trials will show if these agents can satisfy unmet demand in this area.en_US
dc.identifier.doi10.1007/s12029-020-00497-7
dc.identifier.endpage1196en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid32869146en_US
dc.identifier.scopus2-s2.0-85090005792en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1193en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00497-7
dc.identifier.urihttps://hdl.handle.net/11616/99506
dc.identifier.volume51en_US
dc.identifier.wosWOS:000565164500002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvanten_US
dc.subjectNeoadjuvanten_US
dc.subjectImmunotherapyen_US
dc.titleWhy Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu